Form 4: Bio-Rad EVP Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Bio-Rad Laboratories EVP James Barry sold 699.873 shares of Class A Common Stock for approximately $306.18 per share on November 6, 2025, under a pre-arranged 10b5-1 plan.
Summary
- James Barry, Executive Vice President and President of the Life Science Group (LSG) at Bio-Rad Laboratories, Inc., reported a sale of common stock.
- The transaction involved the disposition of 699.873 shares of Bio-Rad A Common Stock.
- The shares were sold on November 6, 2025, at a weighted average price of $306.182 per share.
- The sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.
- The individual sales prices ranged from $306.104 to $306.230 per share.
- Following this transaction, James Barry beneficially owns 509.682 shares of Bio-Rad A Common Stock.
Sentiment
Score: 5
Explanation: The filing reports a routine insider sale under a pre-arranged 10b5-1 plan, which is a common practice for executives for personal financial planning and diversification. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment sentiment. Therefore, the sentiment is neutral.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing reports a routine insider stock transaction and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding insider trading activity, confirming a pre-scheduled sale by a key executive, which is a standard disclosure for public companies.
Key Dates
| Date | Description |
|---|---|
| 11/06/2025 | Date of earliest transaction (sale of Bio-Rad A Common Stock) |
| 11/08/2025 | Date the Form 4 was signed by the reporting person |
Recommendation
holdThe filing reports a pre-scheduled insider sale under a 10b5-1 plan, which is a common practice for executives for personal financial planning and diversification. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the fundamental outlook remains unchanged based solely on this filing.
Keywords
Bio-Rad Laboratories, BIO, BIO.B, Form 4, Insider Sale, James Barry, Stock Transaction, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.